Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
CLOZAPINE
Novartis Pharmaceuticals UK Ltd
N05AH02
CLOZAPINE
25 Milligram
Tablets
Product subject to prescription which may not be renewed (A)
Antipsychotics
Authorised
1992-05-14
1 PACKAGE LEAFLET: INFORMATION FOR THE USER CLOZARIL 25 MG TABLETS_ _ CLOZARIL 100 MG TABLETS_ _ clozapine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Clozaril is and what it is used for 2. What you need to know before you take Clozaril 3. How to take Clozaril 4. Possible side effects 5. How to store Clozaril 6. Contents of the pack and other information 1. WHAT CLOZARIL IS AND WHAT IT IS USED FOR The active ingredient of Clozaril is clozapine which belongs to a group of medicines called antipsychotics (medicines that are used to treat specific mental disorders such as psychosis). Clozaril is used to treat people with schizophrenia in whom other medicines have not worked. Schizophrenia is a mental illness which affects how you think, feel and behave.You should only use this medicine if you have already tried at least two other antipsychotic medicines, including one of the newer atypical antipsychotics, to treat schizophrenia, and these medicines did not work, or caused severe side effects that cannot be treated. Clozaril is also used to treat severe disturbances in the thoughts, emotions and behaviour of people with Parkinson’s disease in whom other medicines have not worked. 2. WHA Lees het volledige document
SUMMARY OF PRODUCT CHARACTERISTICS CLOZARIL CAN CAUSE AGRA NULOCYTOSIS. ITS USE SHOULD BE LIMITED TO PATIENTS: - WITH SCHIZOPHRENIA WHO ARE NON-RESPONSIVE TO OR INTOLERANT OF ANTIPSYCHOTIC MEDICATION, OR WITH PSYCHOSIS IN PARKINSON’S DISEASE WHEN OTHER TREATMENT STRATEGIES HAVE FAILED (SEE SECTION 4.1), - WHO HAVE INITIALLY NORMAL LEUKOCYTE FINDINGS (WHITE BLOOD CELL COUNT 3500/MM 3 ( 3.5X10 9 /L), AND ANC 2000/MM 3 ( 2.0X10 9 /L)), AND - IN WHOM REGULAR WHITE BLOOD CELL (WBC) COUNTS AND ABSOLUTE NEUTROPHIL COUNTS (ANC) CAN BE PERFORMED AS FOLLOWS: WEEKLY DURING THE FIRST 18 WEEKS OF TREATMENT, AND AT LEAST EVERY 4 WEEKS THEREAFTER THROUGHOUT TREATMENT. MONITORING MUST CONTINUE THROUGHOUT TREATMENT AND FOR 4 WEEKS AFTER COMPLETE DISCONTINUATION OF CLOZARIL (SEE SECTION 4.4.). PRESCRIBING PHYSICIANS MUST COMPLY FULLY WITH THE REQUIRED SAFETY MEASURES. AT EACH CONSULTATION, A PATIENT RECEIVING CLOZARIL MUST BE REMINDED TO CONTACT THE TREATING PHYSICIAN IMMEDIATELY IF ANY KIND OF INFECTION BEGINS TO DEVELOP. PARTICULAR ATTENTION MUST BE PAID TO FLU-LIKE COMPLAINTS SUCH AS FEVER OR SORE THROAT AND TO OTHER EVIDENCE OF INFECTION, WHICH MAY BE INDICATIVE OF NEUTROPENIA (SEE SECTION 4.4). CLOZARIL MUST BE DISPENSED UNDER STRICT MEDICAL SUPERVISION IN ACCORDANCE WITH OFFICIAL RECOMMENDATIONS (SEE SECTION 4.4). MYOCARDITIS CLOZAPINE IS ASSOCIATED WITH AN INCREASED RISK OF MYOCARDITIS WHICH HAS, IN RARE CASES, BEEN FATAL. THE INCREASED RISK OF MYOCARDITIS IS GREATEST IN THE FIRST 2 MONTHS OF TREATMENT. FATAL CASES OF CARDIOMYOPATHY HAVE ALSO BEEN REPORTED RARELY (SEE SECTION 4.4). MYOCARDITIS OR CARDIOMYOPATHY SHOULD BE SUSPECTED IN PATIENTS WHO EXPERIENCE PERSISTENT TACHYCARDIA AT REST, ESPECIALLY IN THE FIRST 2 MONTHS OF TREATMENT, AND/OR PALPITATIONS, ARRHYTHMIAS, CHEST PAIN AND OTHER Lees het volledige document